Skip to main content

Table 1 Participant characteristics and associations with cancer-related dietary changes and dietary supplement use

From: Exploring dietary changes and supplement use among cancer patients in Norway: prevalence, motivations, disclosure, information, and perceived risks and benefits: a cross sectional study

 

Total

Women

Men

 

Dietary changes

Dietary supplements

 

%

n = 468

%

n = 315

%

n = 153

p-value

%

n = 373

p-value

%

n = 340

p-value

Sex

         

0.240*

  

0.307*

Women

67.3

315

     

80.1

246

 

78.0

234

 

Men

32.7

153

     

84.7

127

 

73.6

106

 

Age

      

< 0.001*

  

0.675*

  

0.035*

19–50 years

23.1

100

27.9

81

13.3

19

 

83.0

83

 

67.0

67

 

51–64 years

41.3

179

43.4

126

37.1

53

 

79.3

142

 

80.4

144

 

65–82 years

35.6

154

28.6

83

49.7

71

 

82.5

127

 

77.8

119

 

Mean age years (SD)

59.18 (11.295)

57.34 (11.277)

62.92 (10.408)

< 0.001**

58.98 (11.455)

0.444**

59.43 (11.420)

0.889**

Education

      

0.319*

  

0.223*

  

0.502*

Primary school

6.5

28

5.2

15

9.1

13

 

71.4

20

 

67.9

19

 

Secondary school

30.3

131

29.3

85

32.2

46

 

85.5

112

 

77.7

101

 

College/ University < 4 years

33.9

147

35.9

104

30.1

43

 

78.2

115

 

74.1

109

 

College/ University ≥ 4 years

29.3

127

29.7

86

28.7

41

 

82.7

105

 

79.5

101

 

Household income

      

0.477*

  

0.937*

  

0.482*

Low (Less than EUR 40 000)

10.4

45

10.3

30

10.5

15

 

80.0

36

 

75.6

34

 

Middle (EUR 40 000 to 79 000)

35.1

152

35.9

104

33.6

48

 

80.3

122

 

72.4

110

 

High (EUR 80 000 or more)

46.4

201

44.5

129

50.3

72

 

82.6

166

 

79.5

159

 

No reply

8.1

35

9.3

27

5.6

8

 

80.0

28

 

77.1

27

 

Household1

             

Live alone

20.7

97

22.9

72

16.3

25

0.103*

80.4

78

0.730*

77.3

75

0.845*

Live with a partner

66.9

313

62.9

198

75.2

115

0.008*

81.5

255

0.903*

76.6

239

0.984*

Live with own children

18.2

85

21.3

67

11.8

18

0.012*

78.8

37

0.461*

68.2

58

0.043*

Other

1.5

7

1.6

5

1.3

2

1.000^

100

7

0.359^

71.4

5

0.668^

Place of residence (region)

      

0.460*

  

0.041^

  

0.384^

South-East

51.7

242

53.3

168

48.4

74

 

79.9

191

 

73.7

171

 

South

4.3

20

4.1

13

4.6

7

 

70.0

14

 

80.0

16

 

West

24.8

116

22.5

71

29.4

45

 

83.9

94

 

77.1

84

 

Central (Trøndelag)

8.5

40

8.3

26

9.2

14

 

75.0

27

 

77.8

28

 

North

10.7

50

11.7

34

8.5

13

 

94.0

47

 

87.2

41

 

Cancer site1

             

Breast

39.1

183

57.8

182

0.7

1

< 0.001*

75.4

135

0.006*

77.5

134

0.726*

Gastro intestinal

13.7

64

10.5

33

20.3

31

0.004*

87.3

55

0.210*

80.3

49

0.456*

Male genitalia

11.1

52

-

-

34.0

52

-

84.3

43

0.598*

66.7

32

0.086*

Female genitalia

8.1

38

12.1

38

-

-

-

84.2

32

0.667*

94.6

35

0.007*

Lymphoma

8.8

41

6.3

20

13.7

21

0.008*

78.0

32

0.536*

82.9

34

0314*

Malignant melanoma

4.7

22

4.4

14

5.2

8

0.707*

90.9

20

0.249*

59.1

13

0.047*

Head and neck

3.8

18

1.6

5

8.5

13

< 0.001*

83.3

15

0.848*

82.4

14

0.773^

Lung

3.2

15

2.5

8

4.6

7

0.268^

78.6

11

0.765*

85.7

12

0.536^

Sarcoma

3.0

14

3.8

12

1.3

2

0.160^

78.6

11

0.765*

78.6

11

1.000^

Leukemia

2.4

11

2.2

7

2.6

4

0.755^

90.9

10

0.421*

72.7

8

0.724^

Bone marrow

2.1

10

1.9

6

2.6

4

0.735^

100

10

0.129^

70.0

7

0.705^

Other cancer sites

14.3

67

10.8

34

21.6

33

0.002*

90.5

57

0.051*

74.2

46

0.633*

In active cancer treatment

      

0.332*

  

0.034*

  

0.277*

Yes

33.8

158

35.2

111

30.7

47

 

87.0

134

 

79.6

121

 

No

66.2

310

64.8

204

69.3

106

 

78.9

239

 

75.0

129

 

Late and long-term effects

      

 0.045*

  

 0.064*

  

 0.041*

No

11.5

50

8.9

26

16.8

24

 

70.0

35

 

64.0

32

 

Yes, the following:

82.9

360

84.9

247

79.0

113

 

83.1

299

 

78.6

282

 

Fatigue

54.9

257

58.4

184

47.7

73

0.029*

84.0

216

0.129*

80.5

207

0.021*

Sleep disorder

38.5

180

45.7

144

23.5

36

< 0.001*

85.6

154

0.080*

82.2

148

0.020*

Hot flushes

36.3

170

46.0

145

16.3

25

< 0.001*

81.2

138

0.851*

81.8

139

0.042*

Nerve damage (polyneuropathy)

35.3

165

42.2

133

20.9

32

< 0.001*

83.0

137

0.558*

82.4

136

0.025*

Pain

34.0

159

40.0

126

21.6

33

< 0.001*

83.0

132

0.573*

78.6

125

0.448*

Decreased muscle strength and mobility

33.8

158

39.4

124

22.2

34

< 0.001*

83.5

132

0.440*

80.3

126

0.176*

Cognitive challenges

31.8

149

41.0

129

13.1

20

< 0.001*

84.6

126

0.258*

83.2

124

0.019*

Sexual problems

29.3

137

26.7

84

34.6

53

0.075*

83.9

115

0.402*

78.8

108

0.453*

Gained weight

25.2

118

30.8

97

13.7

21

< 0.001*

86.4

102

0.116*

83.9

88

0.028*

Anxiety or depression

20.5

96

22.5

71

16.3

25

0.119*

91.7

88

0.004*

86.5

83

0.010*

Early menopause

19.2

90

28.6

90

-

-

-

77.8

70

0.294*

82.2

74

0.157*

  1. * Pearson chi-square test; ^Fisher exact test
  2. ** Independent sample t-test
  3. 1Multiple choice